CYCCP - Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Benzinga
BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company's fadraciclib will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. The data will be presented at three poster sessions and report activity and antitumor effects of fadraciclib in biliary tract cancer, lung cancer, Richter transformation and lymphoma cell lines.
Details of the presentations are as follows:
| Title: |
| The CDK2/9 inhibitor fadraciclib is active in Richter transformation and lymphoma cell lines by targeting both cell survival and proliferation |
| Abstract No: |
| 518 / 15 |
| Session Topic: |
| Session PO.ET05.01 - Cell Cycle, Transcription Regulation, and Anticancer Drug Action |
| Date and Time: |
| April 7, 2024, 1:30 PM - 5:00 PM PT |
| Location: |
| Exhibition Hall, Section 21 |
| Title: |
| Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers |
| Abstract No: |
| 2117 / 8 |
| Session Topic: |
| Session PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response |
| Date and Time: |
| April 8, 2024, 9:00 AM - 12:30 PM PT |
| Location: |
| Exhibition Hall, Section 30 |
| Title: |
| Anti-tumor ... |